Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: Does it make a difference in the mind and the daily practise of gynaecologists and general practitioners

European Journal of Contraception and Reproductive Health Care

Volumn 14, Issue 4, 2009, Pages 258-267

  Bitzer, J ^a   Frey, B ^a   Von Schonau M ^b   Sabler, N ^a   Tschudin, S ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

^b Bayer Schering Pharma ^*  (Switzerland)

Author keywords

Age; Clinical decision making; Dosage; Ethinyloestradiol; Evidence based medicine; Headache; Oral contraceptives; Side effects; Smoking; Venous thromboembolism

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; UNCLASSIFIED DRUG; YASMINELLE; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACNE; ADULT; ARTICLE; BODY MASS; BREAST TENDERNESS; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG DOSE COMPARISON; FAMILY HISTORY; FEMALE; GENERAL PRACTITIONER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SPECIALIST; MENSTRUAL IRREGULARITY; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; VENOUS THROMBOEMBOLISM; CLINICAL PRACTICE; CONTRACEPTION; DRUG ADMINISTRATION; GENERAL PRACTICE; HEALTH PERSONNEL ATTITUDE; MALE; METHODOLOGY; MIDDLE AGED; STATISTICS; SWEDEN; WOMEN'S HEALTH;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ESTROGENS; ETHINYL ESTRADIOL; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROGESTINS; QUESTIONNAIRES; SWEDEN; WOMEN'S HEALTH;

EID: 70349577991     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180902968856     Document Type: Article

References (20)

1. Anonymous. Oral contraceptives and cardiovascular risk. Drug Ther Bull 2000;38:1-5.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-1727
3. Gerstman BB, Gross PT, Kennedy DL, et al. Trends in the content and use of oral contraceptives in the United States: 1964-1988. Am J Public Health 1991;81:90-96
4. Lawson JS, Yuliano SE, Pasquale SA, Osterman JJ. Optimum dosage of an oral contraceptive. Am J Obstet Gynecol 1979;134:315-320
5. Elstein M. Low dose contraceptive formulations. Is further reduction in steroid dosage justified? Adv Contracept 1994;10:1-4.
6. Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus 30 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; Issue 2 CD 003989.
7. Sidney S, Pettiti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogen- progestin oral contraceptives. Contraception 2004; 70:3-10.
8. Hatcher RA, Guillebaud J. The pill; combined oral contraceptives. In Hatcher RA, Trussell J, Stewart F, et al., eds. Contraceptive technology. 17th edn. New York: Ardent Media Inc 1998:405-466
9. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: A critical review of the literature. Adv Contracept 1992;8(Suppl. 1):35-45.
10. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-582
11. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 mg desogestrel and either 30 mg or 20 mg ethinyl oestradiol Br J Obstet Gynaecol 1993;100: 832-838
12. Pettiti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross sectional study in an international population. TheWHOStudy of Hormonal Contraception and Bone Health. Obstet Gynecol 2000;95:736-744
13. Paolettti AM, Orru M, Floris S, et al. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception 2000; 61:259-263
14. Winkler UH, Holscher T, Schulte J, et al. Ethinylestradiol 20 versus 30 mg combined with 150 mg desogestrel: A large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecol Endocrinol 1996;10:265-271
15. Endrikat J, Kiplling C, Gerlinger C, et al. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 mg ethinyl estradiol and 75 mg gestodene and a 21-day regimen with 30 mg ethinyl estradiol and 75 mg gestodene on hemostatic variables, lipids and carbohydrate metabolism. Contraception 2001;64:235-241
16. Basdevant A, Conard J, Pelissier C, et al. Hemostatic and metabolic effects of lowering the ethinyl estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception 1003;48:193-204.
17. Melis GB, Fruzzetti F, Nicoletti I, et al. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 mg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991;43:21-31.
18. Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 mg or 30 mg ethinylestradiol. Contraception 1996;53:75-84.
19. Lete I, Doval JL, Perez-Campos E, et al. Factors affecting women's selection of a combined hormonal contraceptive method. The TEAM-06 Spanish Cross Sectional Study. Contraception 2007;76:77-83.
20. Murphy PA, Brixner D. Hormonal contraceptives discontinuation patterns according to formulation: Investigations of associations in an administrative claims database. Contraception 2008;77:257-263